The joint venture, which is a 50-50 partnership deal, is expected to provide active pharmaceutical ingredients (API) to various other pharmaceutical firms.
With this manufacturing plant, the companies are expected to offer drugs related to oncology, central nervous system (CNS) cardio vascular diseases (CVD) and will be able to handle 4-6 products at a time.